Drug intelligence / Profile preview

LDE-etoposide

Development stage: Unknown
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

LDE-etoposide is a lipid-based nanoformulation of etoposide that utilizes a lipid nanoemulsion delivery system. The LDE particle mimics the structure of low-density lipoprotein (LDL) and is designed to target cancer cells that overexpress LDL receptors. This formulation aims to improve the therapeutic index of etoposide by enhancing tumor cell uptake while reducing systemic toxicity. The etoposide component works by inhibiting DNA topoisomerase II, preventing DNA re-ligation and leading to cell cycle arrest and apoptosis in cancer cells.

Other names: lipid nanoemulsion etoposideLDE etoposide

Targets

LDLR (Low-density lipoprotein receptor)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on LDE-etoposide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LDE-etoposide.

Explore the full profile